VI
Viyash Scientific Ltd (VIYASH)
₹261.95
Mkt cap
₹11,614 Cr
P/E ratio
52.40
P/B
3.93
Div yield
0.00%
ROE
7.39%
ROCE
13.40%
EPS (TTM)
₹5.00
Book value
₹67
52W range
176–294
Sector
Healthcare
Price history
Previous close
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
NSE VIYASHBSE 512529
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthHigh
TechnicalsNeutral
52-week range
−10.95% from high₹262
₹176+48.49% from low₹294
Current
₹261.95
Prev close
₹263.75
Day
−0.68%
Price performance
1D
−0.68%
1W
−0.13%
1M
−4.28%
3M
+3.82%
6M
+29.57%
1Y
+52.46%
YTD
+24.45%
Financials
Revenue, profit & margin
P/E ratio
52.4×
VIYASH is 49% above the sector median of 35.1×
VIYASH52.4×
Sector median35.1×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 333 | 346 | 329 | 361 | 390 | 369 | 774 | 402 | 792 | 850 | 858 | 920 | 946 | |
| Expenses | 341 | 331 | 307 | 329 | 348 | 330 | 674 | 355 | 673 | 677 | 683 | 736 | 768 | |
| Operating Profit | -8 | 15 | 22 | 32 | 42 | 39 | 100 | 46 | 119 | 173 | 176 | 184 | 178 | |
| OPM % | -2.5% | 4.4% | 7% | 9% | 11% | 11% | 13% | 12% | 15% | 20% | 20% | 20% | 19% | |
| Other Income | -23 | 10 | 7 | -1 | 3 | 0 | 4 | 1 | 6 | 6 | -27 | 16 | 8 | |
| Interest | 10 | 13 | 13 | 12 | 16 | 14 | 21 | 15 | 20 | 18 | 17 | 15 | 13 | |
| Depreciation | 14 | 15 | 15 | 16 | 16 | 17 | 58 | 16 | 56 | 59 | 59 | 60 | 62 | |
| Profit before tax | -56 | -3 | 1 | 3 | 12 | 8 | 24 | 16 | 48 | 102 | 73 | 125 | 112 | |
| Tax % | -38% | 123% | -617% | 52% | 24% | 20% | -71% | 36% | 24% | 29% | 34% | 47% | 29% | |
| Net Profit | -35 | -7 | 11 | 1 | 9 | 6 | 42 | 10 | 37 | 73 | 49 | 66 | 79 | |
| EPS in Rs | -1.40 | -0.34 | 0.33 | -0.04 | 0.26 | 0.10 | 1.78 | 0.37 | 1.27 | 2.18 | 0.88 | 1.19 | 1.51 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.50% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 11 Aug '26 |
| Earnings day | +0.50% |
| +1 day | +1.86% |
| +5 days | +3.81% |
| +15 days | −0.90% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202661.31%Promoter
Promoters61.31%
FIIs4.50%1.56
DIIs3.76%4.22
Public30.34%2.67
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| VIYASH | ₹263.65 | 52.42 | 11,614 | 0.00% | 79 | +103.59% | 946 | +19.54% | 13.42% |
| Median: 159 Co. | ₹423.00 | 35.07 | 2,282 | 0.08% | 13 | +29.60% | 162 | +18.62% | 15.04% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts61
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTNov 2025PPTNov 2025TranscriptAug 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 4 SepDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 27 AugAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript 16 AugAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 12 Aug - Audio recording of Q1 FY2026-27 earnings call for unaudited results is available online.Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Aug - Newspaper Publication for Financial Results of Q1 FY 27.